Mirvie, a company bringing a personalized, predictive, and preventive approach to pregnancy health, today announced two new key additions to the executive team: Dr. Thomas McElrath M.D., Ph.D. as Vice President of Clinical Development and Dr. Lee N. Newcomer M.D. as the Senior Advisor on market access.
As May marks Preeclampsia Awareness Month, leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, “Preeclampsia Prevention is Possible."
A new study in BMC Pregnancy and Childbirth finds that objective information about risk of preeclampsia could be key to driving patient behavior change and creates motivation among pregnant patients to follow provider recommendations on prevention, even among those who are medication-hesitant.
Mirvie, a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced its South San Francisco-based laboratory has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.
Mirvie’s commitment to global maternal health supported by funding from Bill & Melinda Gates Foundation for study to predict preeclampsia, a leading cause of maternal mortality worldwide using the Mirvie RNA platform
Recommendations for high-risk expecting parents and health care providers to promote the prevention of preeclampsia, a leading cause of pregnancy-related death in the United States
Mirvie's report spotlights urgent education opportunities as only 1 in 10 pregnant individuals or those who gave birth could correctly identify all the most common preeclampsia warning signs and symptoms
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the appointment of Alison Cowan, M.D., M.S.C.R. as Head of Medical Affairs. Dr. Cowan will guide Mirvie’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which is first to predict preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy.1
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced it has raised a total of $90 million to date following the close of its Series B funding. The financing was led by Decheng Capital with additional funding from funds and accounts managed by BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield as well as a debt facility with Comerica Bank. The funding will support Mirvie’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which is the first to predict preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy.
